Results of multivariate Cox proportional hazards regression analysis of risk factors in relation to myeloid engraftment (absolute neutrophil count > 5 × 108/L)
| Factor . | RR . | 95% CI . | P value . | Favorable characteristic . |
|---|---|---|---|---|
| Recipient age (per decade) | 1.04 | 1.01-1.06 | .008 | Younger |
| HLA-A and HLA-B matching | 1.20 | 1.10-1.30 | .0001 | Matched |
| DRB1 match4-150 | 1.16 | 1.04-1.28 | .006 | Matched |
| Recipient CMV serologic status | 0.92 | 0.86-0.98 | .006 | Negative |
| Donor sex | 0.91 | 0.86-0.97 | .004 | Male |
| Cell dose (non–T-cell depleted per 108/kg) | 1.10 | 1.08-1.13 | .0001 | Higher dose |
| Methotrexate prophylaxis for GVHD | 0.64 | 0.58-0.71 | .0001 | No methotrexate |
| Year of marrow infusion | ||||
| 1991-1995 | 1.00 | NA | NA | |
| 1996-1997 | 1.24 | 1.15-1.34 | .0001 | Recent infusion |
| 1998-1999 | 1.13 | 1.05-1.22 | .001 | Recent infusion |
| Factor . | RR . | 95% CI . | P value . | Favorable characteristic . |
|---|---|---|---|---|
| Recipient age (per decade) | 1.04 | 1.01-1.06 | .008 | Younger |
| HLA-A and HLA-B matching | 1.20 | 1.10-1.30 | .0001 | Matched |
| DRB1 match4-150 | 1.16 | 1.04-1.28 | .006 | Matched |
| Recipient CMV serologic status | 0.92 | 0.86-0.98 | .006 | Negative |
| Donor sex | 0.91 | 0.86-0.97 | .004 | Male |
| Cell dose (non–T-cell depleted per 108/kg) | 1.10 | 1.08-1.13 | .0001 | Higher dose |
| Methotrexate prophylaxis for GVHD | 0.64 | 0.58-0.71 | .0001 | No methotrexate |
| Year of marrow infusion | ||||
| 1991-1995 | 1.00 | NA | NA | |
| 1996-1997 | 1.24 | 1.15-1.34 | .0001 | Recent infusion |
| 1998-1999 | 1.13 | 1.05-1.22 | .001 | Recent infusion |
RR indicates relative risk; CI, confidence interval; CMV, cytomegalovirus; GVHD, graft-versus-host disease; and NA, not available.
Includes potential DRB1 match.